The Potential Addition of Long-Acting Injectables for PrEP


What does this form of pre-exposure prophylaxis (PrEP) mean in terms of options and initiation.

Video Highlights

1:18 Kimberly Green, PhD

2:22 S. Wilson Beckham, PhD, MPH, MA

3:44 Renee Heffron, PhD, MPH

4:28 Laura Rusie, ScM

Welcome to our series, 1 Big Question, which asks 1 question to the medical community and we get their feedback on an important infectious disease topic.

In this episode, our 1 Big Question is: Do you think the addition of long-term acting injectables for PrEP will lead to greater utilization of it?

We interviewed Kimberly Green, PhD, global program director, Primary Health Care, PATH; S. Wilson Beckham, PhD, MPH, MA, assistant scientist, Department of Health, Behavior and Society, and Department of International Health—Social & Behavioral Sciences, Johns Hopkins Bloomberg School of Public Health; Renee Heffron, PhD, MPH, associate professor, Global Health, associate professor, Epidemiology, Department of Global Health, University of Washington; and Laura Rusie, ScM director of Data, Evaluation, and Epidemiology, Howard Brown Health.

Watch the video to hear their insights.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.